Bioactive oligopeptides in dermatology: Part II

Experimental Dermatology

Volumn 21, Issue 8, 2012, Pages 569-575

  Reddy, Bobby Y ^a   Jow, Tiffany ^a   Hantash, Basil M ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b Elixir Institute of Regenerative Medicine   (United States)

Author keywords

Antimicrobial peptides; Bioactive peptides; Dermatology; Efficacy; Oligopeptides; Therapeutics; Transdermal delivery

Indexed keywords

ACETYLHEXAPEPTIDE 3; ANTIINFECTIVE AGENT; LEUPHASYL; NEUROTRANSMITTER; OLIGOPEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; RT 001; SYN AKE; SYNTHETIC PEPTIDE; TRIPEPTIDE 3; UNCLASSIFIED DRUG; VIALOX;

DERMAL INFUSION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG POTENCY; DRUG STABILITY; ELECTROPORATION; FRACTIONAL PHOTOTHERMOLYSIS; HUMAN; IONTOPHORESIS; MICRODERMABRASION; NONHUMAN; REVIEW; SONOPHORESIS;

ADMINISTRATION, CUTANEOUS; ANTI-INFECTIVE AGENTS; BIOLOGICAL AGENTS; HUMANS; NEUROTRANSMITTER AGENTS; OLIGOPEPTIDES; SKIN DISEASES;

EID: 84863782642     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2012.01527.x     Document Type: Review

References (53)

1. Lintner K, Peschard O. Int J Cosmet Sci 2000: 22: 207-218.
2. Lupo M P, Cole A L. Dermatol Ther 2007: 20: 343-349.
3. Farwick M, Grether-Beck S, Marini A et al. Exp Dermatol 2011: 20: 602-604.
4. Kruse T, Kristensen H H. Expert Rev Anti Infect Ther 2008: 6: 887-895.
5. Makovitzki A, Avrahami D, Shai Y. Proc Natl Acad Sci USA 2006: 103: 15997-16002.
6. Fjell C D, Hiss J A, Hancock R E et al. Nat Rev Drug Discov 2011: 11: 37-51.
7. Ham S W, Kang M J, Park Y M et al. Bull Korean Chem Soc 2007: 28: 1535-1538.
8. TransMTS™- Macromolecule Transport Technology.
9. Zhang R, Zhou M, Wang L et al. Mol Immunol 2010: 47: 2030-2037.
10. Braff M H, Bardan A, Nizet V et al. J Invest Dermatol 2005: 125: 9-13.
11. Lai Y, Gallo R L. Trends Immunol 2009: 30: 131-141.
12. Bhat S, Milner S. Curr Protein Pept Sci 2007: 8: 506-520.
13. Gallo R L, Nizet V. Curr Allergy Asthma Rep 2003: 3: 402-409.
14. Schröder J M, Harder J. Cell Mol Life Sci 2006: 63: 469-486.
15. Park J H, Park G T, Cho I H et al. Exp Dermatol 2011: 20: 369-371.
16. Harder J, Dressel S, Wittersheim M et al. J Invest Dermatol 2010: 130: 1355-1364.
17. Schauber J, Gallo R L. J Allergy Clin Immunol 2008: 122: 261-266.
18. Guaní-Guerra E, Santos-Mendoza T, Lugo-Reyes S O et al. Clin Immunol 2010: 135: 1-11.
19. Kanthawong S, Bolscher J G, Veerman E C et al. Int J Antimicrob Agents 2010: 36: 447-452.
20. Gläser R, Meyer-Hoffert U, Harder J et al. J Invest Dermatol 2009: 129: 641-649.
21. Lizzi A R, Carnicelli V, Clarkson M M et al. Mini Rev Med Chem 2009: 9: 687-695.
22. Zanger P, Holzer J, Schleucher R et al. J Infect Dis 2009: 200: 1907-1915.
23. Zanger P, Holzer J, Schleucher R et al. Infect Immun 2010: 78: 3112-3117.
24. Fulmer P A, Lundin J G, Wynne J H. ACS Appl Mater Interfaces 2010: 2: 1266-1270.
25. Lee S H, Kim S J, Lee Y S et al. Regul Pept 2011: 166: 36-41.
26. Findlay B, Zhanel G G, Schweizer F. Antimicrob Agents Chemother 2010: 54: 4049-4058.
27. Giuliani A, Pirri G, Rinaldi A C. Methods Mol Biol 2010: 618: 137-154.
28. Spann C T, Taylor S C, Weinberg J M. Dis Mon 2004: 50: 407-421.
29. Baltzer S A, Brown M H. J Mol Microbiol Biotechnol 2011: 20: 228-235.
30. Peschel A, Jack R W, Otto M et al. J Exp Med 2001: 193: 1067-1076.
31. Llobet E, Tomás J M, Bengoechea J A. Microbiology 2008: 154(Pt 12): 3877-3886.
32. Nizet V. Curr Issues Mol Biol 2006: 8: 11-26.
33. Topical Botulinum Toxin Type A for the Treatment of Moderate to Severe Lateral Canthal Lines: Preliminary Safety and Efficacy Results of a Blinded, Randomized, Placebo Controlled Trial Francisco Perez Atamoros, MD Centros Dermatologicos Tennyson, Tennyson, Polanco, Mexico.
34. Centerchem: Argireline®., Barcelona, Spain, accessed 2011.
35. Centerchem: Vialox®., Basel, Switzerland, accessed 2011.
36. Centerchem: Leuphasyl®., Barcelona, Spain, accessed 2011.
37. Centerchem: Syn®-Ake., Basel, Switzerland, accessed 2011.
38. Lopes L B, Brophy C M, Furnish E et al. Pharm Res 2005: 22: 750-757.
39. Antosova Z, Mackova M, Kral V et al. Trends Biotechnol 2009: 27: 628-635.
40. Kastin A J, Arimura A, Schally A V. Arch Dermatol 1966: 93: 471-473.
41. Lopes L B, Collett J H, Bentley M V. Eur J Pharm Biopharm 2005: 60: 25-30.
42. de Leeuw J, de Vijlder H C, Bjerring P et al. J Eur Acad Dermatol Venereol 2009: 23: 505-516.
43. Immordino M L, Dosio F, Cattel L. Int J Nanomedicine 2006: 1: 297-315.
44. Haenssle H A, Riedl P, Buhl T et al. Exp Dermatol 2010: 19: 19-28.
45. Sieg A, Wascotte V. J Drug Target 2009: 17: 690-700.
46. Escobar-Chávez J J, Bonilla-Martínez D, Villegas-González M A et al. J Drug Target 2009: 17: 690-700.
47. Prausnitz M R, Langer R. Nat Biotechnol 2008: 26: 1261-1268.
48. Henchoz Y, Abla N, Veuthey J L et al. J Control Release 2009: 137: 123-129.
49. Rachakonda V K, Yerramsetty K M, Madihally S V et al. Pharm Res 2008: 25: 2697-2704.
50. Hantash B M, Liu S T. Microdermabrasion and dermalinfusion. In: Pfenninger J L, Fowler G C eds. Pfenninger and Fowler's Procedures for Primary Care. Philadephia, PA: Mosby Inc, 2011: chapter 58.
51. Lee W R, Shen S C, Kuo-Hsien W et al. J Invest Dermatol 2003: 121: 1118-1125.
52. Hantash B M, Mahmood M B. Dermatol Surg 2007: 33: 525-534.
53. Marra D E, Yip D, Fincher E F et al. Arch Dermatol 2006: 142: 1024-1026.